# Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma

> **NCT06674265** · PHASE1 · RECRUITING · sponsor: **Marzieh Ebrahimi** · enrollment: 10 (estimated)

## Conditions studied

- Neuroblastoma, Recurrent, Refractory
- Neuroblastoma (NB)
- Neuroblastoma in Children

## Interventions

- **BIOLOGICAL:** Allogenic NK cells infusion

## Key facts

- **NCT ID:** NCT06674265
- **Lead sponsor:** Marzieh Ebrahimi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674265, "Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06674265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*